Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-β1 levels in serum of patients with atrial fibrillation

BMC Cardiovascular Disorders

JianWei Qin¹  YanHu Wu¹  YongFeng Shao¹  BuQing Ni¹  WeiDong Gu¹  YiJiang Chen¹  ShiJiang Zhang¹  Fei Zhao¹ 

[1] Cardiothoracic Surgery Department, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou RoadJiangsu Province, Nanjing 210029, China

关键词: N-terminal type III procollagen propeptides;    N-terminal type I procollagen propeptides;    Carboxyl terminal peptide from pro-collagen I;    NF-AT4;    NF-AT3;    Transcription factor;    Atrial fibrosis;    Atrial fibrillation;   

Others  :  1088679
DOI  :  10.1186/1471-2261-14-167

 received in 2014-07-08, accepted in 2014-11-17,  发布年份 2014

【 摘 要 】

Background

Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice. Unfortunately, the precise mechanisms and sensitive serum biomarkers of atrial remodeling in AF remain unclear. The aim of this study was to determine whether the expression of the transcription factors NF-AT3 and NF-AT4 correlate with atrial structural remodeling of atrial fibrillation and serum markers for collagen I and III synthesis.

Methods

Right and left atrial specimens were obtained from 90 patients undergoing valve replacement surgery. The patients were divided into sinus rhythm (n = 30), paroxysmal atrial fibrillation (n = 30), and persistent atrial fibrillation (n = 30) groups. NF-AT3, NF-AT4, and collagen I and III mRNA and protein expression in atria were measured. We also tested the levels of the carboxyl-terminal peptide from pro-collagen I, the N-terminal type I procollagen propeptides, the N-terminal type III procollagen propeptides, and TGF-β1 in serum using an enzyme immunosorbent assay.

Results

NF-AT3 and NF-AT4 mRNA and protein expression were increased in the AF groups, especially in the left atrium. NF-AT3 and NF-AT4 expression in the right atrium was increased in the persistent atrial fibrillation group compared the sinus rhythm group with similar valvular disease. In patients with AF, the expression levels of nuclear NF-AT3 and NF-AT4 correlated with those of collagens I and III in the atria and with PICP and TGF-β1 in blood.

Conclusions

These data support the hypothesis that nuclear NF-AT3 and NF-AT4 participates in atrial structural remodeling, and that PICP and TGF-β1 levels may be sensitive serum biomarkers to estimate atrial structural remodeling with atrial fibrillation.

【 授权许可】

   
2014 Zhao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Wyse DG, Gersh BJ: Atrial fibrillation: a perspective: thinking inside and outside the box. Circulation 2004, 109:3089-3095.
• [2]Burstein B, Nattel S: Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008, 51:802-809.
• [3]Ross J Jr: Left ventricular function and the timing of surgical treatment in valvular heart disease. Ann Intern Med 1981, 94:498-504.
• [4]Otto CM: Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol 2006, 47:2141-2151.
• [5]Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
• [6]Lin CS, Pan CH: Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 2008, 65:1489-1508.
• [7]Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J: Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002, 54:361-379.
• [8]Iwasaki YK, Nishida K, Kato T, Nattel S: Atrial fibrillation pathophysiology: implications for management. Circulation 2011, 124:2264-2274.
• [9]Mazzini MJ, Monahan KM: Pharmacotherapy for atrial arrhythmias: present and future. Heart Rhythm 2008, 5:S26-31.
• [10]Li D, Fareh S, Leung TK, Nattel S: Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999, 100:87-95.
• [11]Allessie M, Ausma J, Schotten U: Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002, 54:230-246.
• [12]Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
• [13]Eckstein J, Verheule S, de Groot NM, Allessie M, Schotten U: Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria. Prog Biophys Mol Biol 2008, 97:435-451.
• [14]Swartz MF, Fink GW, Sarwar MF, Hicks GL, Yu Y, Hu R, Lutz CJ, Taffet SM, Jalife J: Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. J Am Coll Cardiol 2012, 60:1799-1806.
• [15]Palmer S, Groves N, Schindeler A, Yeoh T, Biben C, Wang CC, Sparrow DB, Barnett L, Jenkins NA, Copeland NG, Koentgen F, Mohun T, Harvey RP: The small muscle-specific protein Csl modifies cell shape and promotes myocyte fusion in an insulin-like growth factor 1-dependent manner. J Cell Biol 2001, 153:985-998.
• [16]Miyashita T, Takeishi Y, Takahashi H, Kato S, Kubota I, Tomoike H: Role of calcineurin in insulin-like growth factor-1-induced hypertrophy of cultured adult rat ventricular myocytes. Jpn Circ J 2001, 65:815-819.
• [17]Bukowska A, Lendeckel U, Hirte D, Wolke C, Striggow F, Rohnert P, Huth C, Klein HU, Goette A: Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. Cell Mol Life Sci 2006, 63:333-342.
• [18]Diedrichs H, Hagemeister J, Chi M, Boelck B, Muller-Ehmsen J, Schneider CA: Activation of the calcineurin/NFAT signalling cascade starts early in human hypertrophic myocardium. J Int Med Res 2007, 35:803-818.
• [19]Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
• [20]Berry JM, Le V, Rotter D, Battiprolu PK, Grinsfelder B, Tannous P, Burchfield JS, Czubryt M, Backs J, Olson EN, Rothermel BA, Hill JA: Reversibility of adverse, calcineurin-dependent cardiac remodeling. Circ Res 2011, 109:407-417.
• [21]Dickhout JG, Carlisle RE, Austin RC: Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis. Circ Res 2011, 108:629-642.
• [22]Islam M, Burke JF Jr, McGowan TA, Zhu Y, Dunn SR, McCue P, Kanalas J, Sharma K: Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 2001, 59:498-506.
• [23]Shibasaki F, Price ER, Milan D, McKeon F: Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. Nature 1996, 382:370-373.
• [24]Shimoyama M, Hayashi D, Takimoto E, Zou Y, Oka T, Uozumi H, Kudoh S, Shibasaki F, Yazaki Y, Nagai R, Komuro I: Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 1999, 100:2449-2454.
• [25]Herum KM, Lunde IG, Skrbic B, Florholmen G, Behmen D, Sjaastad I, Carlson CR, Gomez MF, Christensen G: Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress. J Mol Cell Cardiol 2013, 54:73-81.
• [26]Lijnen PJ, Petrov VV, Fagard RH: Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 2000, 71:418-435.
• [27]Lopez B, Gonzalez A, Querejeta R, Diez J: The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005, 23:1445-1451.